Clinical development of 17-allylamino, 17-demethoxygeldanamycin.

@article{Sausville2003ClinicalDO,
  title={Clinical development of 17-allylamino, 17-demethoxygeldanamycin.},
  author={Edward A. Sausville and Joseph E. Tomaszewski and Percy S. Ivy},
  journal={Current cancer drug targets},
  year={2003},
  volume={3 5},
  pages={377-83}
}
17-allylamino, 17-demethoxygeldanamycin (17AAG; NSC 330507) is the first modulator of heat shock protein 90 (Hsp90) to enter clinical trials. Hsp90 serves a chaperone role to properly fold and deliver client proteins to appropriate intracellular locations. Interest in Hsp90 modulators for the experimental therapeutics of cancer has arisen based on pre-clinical evaluations suggesting that Hsp90 client proteins regulate signaling pathways critical to the molecular economy of many types of tumors… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 82 extracted citations

Rational design of shepherdin, a novel anticancer agent.

Cancer cell • 2005
View 5 Excerpts
Highly Influenced

Targeted therapy by disabling crossroad signaling networks: the survivin paradigm.

Molecular cancer therapeutics • 2006
View 8 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…